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Abstract
Overview: To investigate whether serum ischemia-modified albumin or C-reactive protein is reliable for predicting type 2 diabetic 
patients with ketosis.
Approach: One hundred and four diabetic patients, 48 with diabetic ketosis, and 33 controls were enrolled in the study. Serum ischemia-
modified albumin and C-reactive protein were measured and evaluated for their ability to distinguish diabetic ketosis.
Results: Compared to the controls, the ischemia-modified albumin and C-reactive protein levels were higher in patients with diabetic 
ketosis and type 2 diabetes at the baseline. The levels of ischemia-modified albumin were higher in patients with type 2 diabetes than 
in the controls. C-reactive protein and ischemia-modified albumin levels were reduced after insulin treatment. The level of ischemia-
modified albumin was an independent risk marker for diabetic ketosis (OR = 1.085, P = 0.008, 95% CI: 1.022–1.152). Receiver operating 
characteristic curves revealed that the areas under the curve were 0.917 for the modified albumin and 0.357 for C-reactive protein.
Conclusion: This study indicates that ischemia-modified albumin was significantly associated with diabetic ketosis and was more 
sensitive than C-reactive protein in reflecting diabetic ketosis.
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Introduction
Ischemia-modified  albumin  (IMA)  is  a  promising 
  biomarker  for  evaluating  patients  with  ischemic 
events. In many diseases that are accompanied by 
ischemia, the serum levels of IMA rise.1,2 The precise 
mechanism of how IMA is produced is not known 
but appears to be related to the production of reactive 
oxygen species that modify the metal binding sites.2,3 
Data  exist  suggesting  that  IMA  is  not  specific  for 
  cardiac ischemia and is also elevated in patients with 
liver  cirrhosis,4  pulmonary  embolism,5  end-stage 
renal disease,6 and cerebrovascular diseases.7,8
Oxidative  stress  has  been  implicated  in  the 
development  of  chronic  complications  related  to 
diabetes  mellitus.9  Some  previous  studies  have 
reported that compared to healthy controls, patients 
with type 2 diabetes (T2D) and chronic microvascular 
complications have higher serum levels of IMA.10–12 
To our knowledge, there are no data regarding the 
levels of IMA in patients with type 2 diabetic ketosis 
(T2DK) without ketoacidosis (ie, diabetic ketonuria). 
T2DK, as an acute complication of diabetes mellitus, 
was accompanied by significant hyperglycemia and 
most likely reflects relative insulinopenia. Only 23% 
of the episodes of ketonuria were acknowledged in the 
progress notes.13 Ketonuria occurs more frequently 
than ketoacidosis in patients with T2D and may be 
portentous of serious future events.14
C-reactive protein (CRP) is a type I acute phase 
response  protein  that  is  synthesized  in  the  liver.15 
CRP has been established as a marker for diabetic 
ketoacidosis.16 Both chronic and acute complications 
related to diabetes can lead to the potent production 
of free radicals and pro-inflammatory cytokines.9,17 
  However,  it  is  unknown  if  there  are  differences 
regarding IMA or CRP in patients with T2DK and 
T2D.  Importantly,  is  the  IMA  or  CRP  better  at 
  predicting T2DK?
In the present study, we examined IMA and CRP 
levels in T2D subjects with and without ketosis. We 
also  assessed  the  association  between  the  serum 
IMA and several metabolic parameters affecting the 
subjects.
Methods
Study design and exclusion criteria
This controlled study was performed at the Department 
of  Endocrinology  and  Metabolism,  the  affiliated 
Huai`an hospital of Xuzhou Medical College from 
April 2010 to July 2011. The study was approved by 
the ethics committee of the hospital. Informed   consent 
was obtained from all of the participants.
Fifty-six  consecutive  adult  subjects  with  T2D, 
48  T2DK  subjects  with  diabetic  ketosis  and  33 
control subjects (Table 1) participated in the study. 
Patients  with  T2DK,  who  were  negative  for  the 
glutamic  acid  decarboxylase  autoantibody,  were 
treated  with  oral  hypoglycemic  agents,  insulin,  or 
diet control.   Diabetic ketosis was defined as having 
a blood glucose . 11.1 mmol/L, moderate to large 
(+∼+++)  urine  ketones,  and  a  normal  blood  pH 
range (7.35–7.45). The exclusion criteria included: 
pregnancy, acute alcohol intoxication, type 1 diabetes, 
or T2D with a history of ischemic events. Patients 
with hepatic, renal, or cardiac insufficiency were also 
excluded. Also excluded were patients with signs of 
secondary  inflammatory  conditions,  electrocardiogram 
abnormalities at the time of admission or those who 
had a previous corticosteroid treatment. The control 
  subjects, who had no clinical evidence of a major 
  disease, were recruited from an unselected population 
that underwent a routine medical check-up.
All  T2DK  subjects  received  medical  nutrition 
therapy and 4 times daily insulin injections of human 
insulin.  The  outcome  was  followed  up  until  the 
ketonuria was eliminated.
Biochemical analyses
The  body  mass  index  was  calculated  as  the  body 
weight  in  kilograms  divided  by  height  in  meters 
squared. Blood samples were drawn from T2D and 
control subjects and dispensed into vacutainer tubes 
by  venipuncture  in  a  fasting  state  (10  hours).  In 
patients with T2DK, the blood samples were drawn 
(a)  at  the  time  of  presentation,  before  the  initial 
therapy and (b) 120 hours after the administration of 
fluids and insulin.
The blood samples were centrifuged and stored at   
−20 °C for a maximum of four weeks before measuring 
for IMA. The levels of serum IMA were measured using 
a commercial kit (Co-Health Laboratories Co., Ltd., 
Beijing, China) on an Olympus AU 2700 autoanalyzer 
(Olympus, Tokyo, Japan). The levels of serum CRP was 
assayed with the immunonephelometric method (Dade 
Behring Marburg, Marburg, Germany). The reference 
concentrations for IMA and CRP were ,77.6 U/mL Ischemia-modified albumin in diabetic ketosis
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Table 1. clinical and biochemical characteristics of the study participants.
Variable control (n = 33) T2D (n = 56) T2DK (n = 48)
Female/Male (n) 10/23 20/36 12/36
Age (years) 
Systolic blood pressure (mmhg) 
Diastolic blood pressure (mmhg) 
Body mass index (kg/m2) 
Fasting plasma glucose (mmol/L) 
2-hour post plasma glucose (mmol/L) 
glycated hemoglobin A1c (%) 
Serum uric acid (μmol/L) 
Serum creatinine (μmol/L) 
Serum albumin (g/L) 
Total cholesterol (mmol/L) 
Triglycerides (mmol/L) 
 
high-density lipoprotein cholesterol (mmol/L) 
Low-density lipoprotein cholesterol (mmol/L) 
c-reactive protein (mg/L) 
Ischemia-modified albumin (U/mL)
52.45 ± 11.66 
144 ± 15 
89 ± 11 
24.23 ± 2.91 
5.07 ± 0.74 
6.12 ± 1.02 
5.94 ± 0.29 
307.23 ± 76.92 
73.50 ± 14.06 
42.02 ± 3.14 
4.47 ± 1.01 
1.32 
(0.26–4.11) 
1.19 ± 0.32 
2.84 ± 0.86 
2.31 ± 0.65 
46.31 ± 11.42
52.78 ± 9.72 
145 ± 18 
88 ± 10 
25.58 ± 2.10 
9.45 ± 2.19** 
14.23 ± 3.51** 
9.64 ± 2.55** 
280.93 ± 72.08 
75.56 ± 11.42 
42.08 ± 3.96 
4.86 ± 1.13 
2.33* 
(0.56–10.47) 
1.21 ± 0.35 
2.81 ± 0.64 
4.21 ± 1.21* 
61.47 ± 10.93**
53.98 ± 11.67 
145 ± 15 
89 ± 10 
25.78 ± 3.06 
16.36 ± 3.21**,§ 
19.22 ± 5.62**,§ 
10.76 ± 3.40**,§§ 
285.85 ± 61.09 
74.92 ± 13.36 
40.51 ± 4.56 
4.80 ± 1.47 
1.92 
(0.55–7.23) 
1.08 ± 0.24 
2.78 ± 0.66 
6.15 ± 1.81**,§§ 
78.15 ± 15.39**,§§
notes: comparison to control group: *P , 0.05, **P , 0.001; comparison to T2D group: §P , 0.05, §§P , 0.001. All values in the table are given as the 
mean ± standard deviation, except for the triglyceride values, which are given as the median and the range (min–max).
and ,3 mg/L, respectively. The intra-assay variability 
for the IMA and CRP was below 4.3%. The levels of 
the glycated hemoglobin A1c (HbA1c) were measured 
using  the  Bio-Rad  Laboratories  (Shanghai,  China) 
Ltd.  HbA1c  Meter.  The  final  HbA1c  test  result  was 
calculated from the HbA1c/Hb ratio. Plasma glucose, 
serum  albumin,  serum  uric  acid,  serum  creatinine, 
lipids, and urine were measured using routine clinical 
assays.
Statistical analyses
The  quantitative  data  were  presented  as  the 
mean ± standard deviation. Statistical analyses were 
conducted with the SPSS 11.0 package (SPSS Inc., 
Chicago, IL) for Windows. A comparative analysis 
among the three groups was carried out using the 
Student Newman-Keuls ANOVA. The Chi-squared 
test was used to compare other clinical features. The 
paired t-test was used to determine the significance 
of  the  changes  in  the  patients  with  T2DK. 
The correlation between the IMA and CRP levels 
and other parameters was examined in all diabetic 
patients using Pearson correlation analysis. Multiple 
linear regression analyses were used to estimate the 
factors affecting the IMA levels. The risk markers 
for  T2DK  were  examined  by  multiple  logistic 
analyses.  To  determine  the  optimal  cutoff  values 
and the diagnostic performance of these variables, 
a  receiver  operating  characteristic  (ROC)  curve 
analysis was performed. The area under the curve 
(AUC) was also used to determine the ability of IMA 
levels to diagnose T2DK. A two-tailed P , 0.05 was 
considered statistically significant.
Results
clinical characteristics
The baseline clinical characteristics of the subjects 
are  shown  in  Table  1. A  total  of  137  cases  were 
included  in  the  study.  The  fasting  plasma  glucose 
(FPG),  2-hour  post  plasma  glucose  (2hPG),  and 
HbA1c were   significantly higher in the subjects with 
T2D and T2DK than in the control group (P , 0.001 
or P , 0.05). There were no significant differences 
among the three groups with respect to age, gender, 
systolic blood pressure, diastolic blood pressure, body 
mass index, serum albumin, serum uric acid, serum 
creatinine, and lipids profile, except for triglycerides.
IMA and crP levels
The mean CRP levels were 2.31 ± 0.65 mg/L in the 
control group, 4.21 ± 1.21 mg/L in the T2D group, and 
6.15 ± 1.81 mg/L in the T2DK group. The differences 
in CRP levels among the three groups were statistically 
significant  (P  ,  0.05).  In  the  group  comparisons, 
there was a statistical difference between the T2DK 
and T2D groups (P , 0.001), the T2DK and control Ma et al
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groups (P , 0.001), and the T2D and control groups 
(P , 0.05). These results are shown in Figure 1.
The  mean  levels  of  serum  IMA  were  46.31  ± 
11.42 U/mL in the control group, 61.47 ± 10.93 U/mL 
in the T2D group, and 78.15 ± 15.39 U/mL in the 
T2DK group. The differences among the three groups 
were statistically significant (P , 0.001). As shown 
in  Figure  2,  serum  IMA  levels  were  significantly 
increased in patients with T2D and T2DK compared 
to the controls (P , 0.001) and were higher in patients 
with T2DK than T2D (P , 0.001). One hundred and 
twenty hours after the treatment, the levels of CRP, 
FPG,  2hPG,  and  IMA  were  reduced  in  the T2DK 
subjects (4.56 ± 1.28 mg/L, 7.56 ± 2.30 mmol/L, 9.75 ± 
4.12 mmol/L, and 56.87 ± 12.44 U/mL, respectively) 
compared  to  the  baseline  (P  =  0.035,  P  ,  0.001, 
P , 0.001, P = 0.01, respectively).
correlation and regression analyses
Bivariate  correlation  analyses  were  performed  to 
assess the relationships between the baseline serum 
IMA  concentrations  and  the  metabolic  parameters. 
There  was  no  significant  correlation  between  the 
levels of IMA and CRP (P = 0.805) or between the 
level of IMA and other variables (all P . 0.05). In 
addition, there was no correlation between the levels 
of CRP and all the metabolic variables (all P . 0.05) 
for  all  the  diabetic  cases.  A  multiple  regression 
analysis showed that diabetic ketosis was independent 
of the factors influencing the levels of serum IMA and 
CRP (β = 0.743, P , 0.001; β = 0.453, P , 0.05, 
respectively)  at  the  baseline.  To  examine  the  risk 
markers  for  T2DK,  a  multiple  logistic  regression 
analysis  of  the  three  significant  clinical  variables 
(CRP, FPG, 2hPG, and IMA) was performed. The 
odds ratios and 95% confidence intervals (CI) were 
calculated. The differences for CRP and IMA were 
statistically significant (OR = 0.860, P = 0.017, 95% 
CI  0.760–0.973;  OR  =  1.085,  P  =  0.008,  95%  CI 
1.022–1.152,  respectively)  (Table  2).  Our  analysis 
shows that the IMA may be more appropriate as a 
risk marker for T2DK.
rOc analyses
ROC  analyses  were  used  to  identify  the  optimal 
serum  IMA  and  CRP  cutoff  values  for  predicting 
T2DK (Fig. 3). We observed a statistically signifi-
cantly higher AUC for the IMA (0.917 ± 0.031) in 
comparison with CRP (0.357 ± 0.060) (P , 0.05). 
The optimum diagnostic cutoff for IMA that maxi-
mally  increased  sensitivity  and  specificity  in  the 
estimation  of  T2DK  was  72.4  U/L  (87.0%  and 
85.7%,   respectively). This point was calculated as 
5.81 mg/L for CRP (57.0% and 65.7%, respectively). 
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Figure 1. The mean crP levels in the control, T2D, and T2DK groups. 
notes: The statistical significances between the groups are indicated as follows: comparison to control group: *P , 0.05, **P , 0.001; comparison to 
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This    indicates  that  compared  to  CRP,  IMA  has  a 
higher diagnostic potential.
Discussion
The major finding of this study is that compared to 
patients  with T2D  and  control  subjects,  the  levels 
of IMA were significantly elevated in patients with 
T2DK.  Diabetic  ketosis  was  the  significant  factor 
influencing  serum  IMA  levels  in  the  participants. 
Insulin treatment had a favorable effect on   glycemic 
control,  IMA  and  CRP  levels.  IMA  was  a  risk 
marker for T2DK and more sensitive than CRP in 
distinguishing T2DK.
In  recent  years,  researchers  have  focused 
their  attention  on  the  pathological  role  of  chronic 
inflammatory and free radicals in T2D. Existing data 
that show that before the complications of diabetes 
become  clinically  evident,  hyperglycemia-induced 
oxidative  stress  occurs.18  IMA  was  a  biochemical 
evaluation based on serum albumin binding to cobalt. 
IMA is not tissue specific and is elevated in subjects 
who  undergo  oxidative  stress  other  than  cardiac 
ischemia. There are concerns about tissue-specificity 
of  IMA,  as  it  has  been  suggested  that  IMA  is  a 
biomarker for other oxidative stress or ischemia-related 
diseases.19 The possible role of IMA was confirmed in 
previous studies.4,6,10–12 In the present study, the T2DK 
patients  had  significantly  poorer  glycemic  control, 
which was associated with an increase in inflammatory 
and  oxidative  stress  biomarkers.  Higher  levels  of 
IMA and CRP were detected in patients with T2D and 
T2DK. Hyperglycemia and inflammation reduces the 
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Table 2. Multiple logistic regression analysis using T2DK as a dependent variable with all diabetic subjects (n = 104).
Variable Multiple logistic regression analysis
Wald  OR P 95% cI
Fasting plasma glucose (mmol/L) 2.948 1.115 0.086 0.985–1.263
2-hour post plasma glucose (mmol/L) 
c-reactive protein (mg/L)
2.102 
5.716
1.012 
0.860
0.121 
0.017
0.863–1.220 
0.760–0.973
Ischemia-modified albumin (U/mL) 7.100 1.085 0.008 1.022–1.152Ma et al
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capacity of albumin to bind cobalt, resulting in higher 
IMA levels.20 Based on the above data, the IMA is 
a relatively new biomarker that may be a valuable 
signal for oxidative stress in patients with T2DK.
Increased  levels  of  oxidative  stress,  pro-
inflammatory  markers,  and  downstream  effector 
adhesion molecules occur in patients with T2D.16,21,22 
T2D  is  intimately  linked  to  hypertriglyceridaemia. 
The level of CRP is increased in diabetic patients 
with severe DKA, even in the absence of an infection, 
and may serve as a marker for systemic inflammatory 
response syndrome.23 Diabetic ketonuria is common 
among newly diagnosed or untreated patients with 
T2D and has been used to predict pathologic features 
or metabolic acidosis.14 Among Japanese patients with 
acute onset diabetic ketosis, there was a preponderance 
of  males.24  The  present  study  obtained  similar 
results: T2DK was poorly controlled and male in the 
majority. An increase in serum IMA was associated 
with  hyperketonemia  in  patients.  However,  there 
was no correlation between the IMA and CRP. CRP 
is regulated by the pro-inflammatory cytokines IL-6, 
IL-1β, and TNF-α.15 The mechanisms of CRP and IMA 
production are apparently different. The results of the 
ROC analysis revealed that IMA could reflect T2DK 
and was superior to CRP. In contrast, plasma CRP 
levels were not sensitive or specific enough to reflect 
T2DK. In agreement with the present study, the IMA 
could be a risk biomarker for T2DK. The sensitivity 
and  specificity  of  the  IMA  depend  on  the  clinical 
characteristics  of  the  patients  under  investigation. 
The contributing factors and associations are being 
elucidated but remain unclear in T2DK states. Further 
studies are required to investigate the role of IMA in 
diabetic crises.
Diabetic ketoacidosis and nonketotic hyperglyce-
mia are two acute hyperglycemic emergencies. The 
plasma levels of pro-inflammatory cytokines, markers 
of oxidative stress, and lipid peroxidation are elevated 
on admission in patients with hyperglycemic crises.25 
The elevated levels of ketone body acetoacetate can 
generate oxygen radicals and cause lipid peroxida-
tion in endothelial cells.26 In diabetic ketotic patients, 
the serum IMA and CRP concentrations were high at 
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the beginning of hospitalization. T2D patients with 
ketonuria were more likely to be treated with insulin 
than those without ketonuria. In this study, the CRP 
and IMA levels were reduced in the T2DK patients, 
and  control  over  plasma  glucose  was  improved. 
T2D eventually leads to absolute or relative insulin 
deficiency. T2DK is the cause of pancreatic β-cells 
aggravation. As evident by a reduction in CRP, during 
T2D, insulin may have a modest anti-inflammatory 
effect.  Insulin  suppresses  pro-inflammatory  cytok-
ines, not only by preventing hyperglycemia but also 
by modulating key inflammatory molecules.27
In summary, the markers CRP and IMA are higher 
in patients with T2DK but decreased following the 
treatments. Increasing levels of IMA were indepen-
dently and significantly associated with T2DK. The 
present results suggest that IMA may be an interest-
ing biomarker for predicting T2DK. The status of the 
proinflammatory  cytokines  and  markers  of  oxida-
tive stress in hyperglycemic crises of diabetic ketosis 
should be explored.
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